SCHEDULE 13G: TCG Crossover Entities Disclose 5.2% Stake in Upstream Bio, Inc.

TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC, and Chen Yu have jointly reported beneficial ownership of 5.2% of Upstream Bio, Inc.'s common stock as of December 31, 2024.

Summary

• TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC, and Chen Yu (collectively, the "Reporting Persons") have jointly filed a Schedule 13G, disclosing their beneficial ownership in Upstream Bio, Inc.
• The Reporting Persons collectively beneficially own 2,801,763 shares of Upstream Bio, Inc.'s Common Stock.
• This ownership represents 5.2% of the total outstanding shares of Upstream Bio, Inc.'s Common Stock.
• The percentage of class was calculated based on 53,596,601 shares of Common Stock outstanding, as reported in Upstream Bio, Inc.'s Form 10-Q filed with the SEC on November 7, 2024.
• TCG Crossover GP I, LLC is the general partner of TCG Crossover Fund I, L.P., and Chen Yu is identified as the sole managing member of TCG Crossover GP II, with all three entities sharing voting and dispositive power over the reported shares.
• The Reporting Persons explicitly disclaim status as a group for the purposes of this Schedule 13G and state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. A 13G filing is primarily a factual disclosure. The slight positive lean comes from the implicit signal of an institutional investor taking a significant stake, which can be viewed as a vote of confidence, though the filing itself is purely informational.

Positives

• The disclosure of a significant institutional stake by TCG Crossover entities may signal investor confidence in Upstream Bio, Inc.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future outlook.

Industry Context

Schedule 13G filings are standard disclosures for institutional investors acquiring significant stakes (5% or more) in publicly traded companies. This filing indicates TCG Crossover's investment in Upstream Bio, Inc., a common occurrence in the investment landscape where funds take positions in companies, often in the biotechnology or life sciences sector given the 'Bio' in the company name.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of beneficial ownership and does not provide financial results or operational metrics that can be directly compared to industry benchmarks or specific comparable companies/projects. It simply reports a significant ownership stake by an investment entity.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may influence market perception and potentially share price, signaling institutional interest.

Key Dates

Keywords

Upstream Bio Inc., TCG Crossover Fund I, TCG Crossover GP I, Chen Yu, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional investment, biotechnology